[{"id":"240b9aa0-4a92-4f04-a2a7-ab97aaffd859","acronym":"","url":"https://clinicaltrials.gov/study/NCT02785068","created_at":"2021-01-18T13:39:46.675Z","updated_at":"2024-07-02T16:37:26.599Z","phase":"Phase 1/2","brief_title":"Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02785068","lead_sponsor":"Merrimack Pharmaceuticals","biomarkers":" EGFR • KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • MM-151"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2017-01-11"}]